ML210-ansaFc (Compound III-13) is a covalent GPX4 inhibitor featuring a [3]-ferrocenyl group, with an IC50 of 3.4 µM. It effectively induces ferroptosis by elevating ROS levels and promoting lipid peroxidation (LPO) in cancer cells. ML210-ansaFc exhibits anticancer activity and inhibits tumor growth in 3D spheroid models, and it is useful for research on cancer treatment resistance.
Target-Kategorie:
Ferroptosis|||ROS|||Glutathione Peroxidase
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
